Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 9:33 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 697–720 of 3,978 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Pathophysiology Clear all

Conditions: Alzheimer Disease
Interventions: 18F-MK-6240, Lumbar Puncture (optional); Drug · Procedure
Lead sponsor: Patrick Lao; Other
Eligibility: 50 Years to 100 Years
Enrollment: 71 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: Alzheimer Disease
Interventions: Anti-amyloid Monoclonal Antibodies (mAbs), Standard of Care; Drug · Combination Product
Lead sponsor: Emory University; Other
Eligibility: 50 Years to 90 Years
Enrollment: 735 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 8
States / cities: Albany, Georgia • Atlanta, Georgia • Augusta, Georgia + 4 more

Conditions: Alzheimer's Disease
Interventions: Simvastatin, L-Arginine, Tetrahydrobiopterin; Drug
Lead sponsor: University of Massachusetts, Worcester; Other
Eligibility: 55 Years to 85 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 1
States / cities: Worcester, Massachusetts

Conditions: Alzheimer's Disease, Mild Cognitive Impairment
Interventions: Gastro-retentive zinc cysteine tablet, Tablet identical physically to active comparator containing some lactose; Other
Lead sponsor: Adeona Pharmaceuticals; Industry
Eligibility: 55 Years to 90 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 3
States / cities: Clearwater, Florida • Holiday, Florida • Port Richey, Florida

Conditions: Dementia, Alzheimers Disease, Mild Cognitive Impairment Due to Alzheimer's Disease
Interventions: Foralumab TZLS-401 50 µg, Foralumab TZLS-401 100 µg; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 60 Years to 85 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hyper-IgE Syndrome, Job's Syndrome
Interventions: Omalizumab (Xolair); Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 6 Years to 76 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Interventions: Echocardiogram Recording, Questionnaire Administration, Stress Cardiac Magnetic Resonance Imaging, Wireless Synchronized Cardiac Function Monitoring Device; Procedure · Other · Device
Lead sponsor: City of Hope Medical Center; Other
Eligibility: Not listed
Enrollment: 149 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Duarte, California

Conditions: Endothelial Dysfunction
Interventions: Exercise Condition, Control Condition; Other
Lead sponsor: Texas Christian University; Other
Eligibility: 45 Years to 70 Years · Female only
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Fort Worth, Texas

Conditions: Overweight and Obesity, Endothelial Dysfunction, Cardiovascular Risk Factor
Interventions: Walnut Intake; Other
Lead sponsor: University of California, Davis; Other
Eligibility: 45 Years to 65 Years · Female only
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Davis, California

Conditions: Chronic Granulomatous Disease
Interventions: Interferon Gamma-1B; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 5 Years to 60 Years
Enrollment: 9 participants
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Coronary Microvascular Dysfunction
Interventions: The Neovasc Reducer™ System; Device
Lead sponsor: Amir Lerman; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Infections, Pneumonia, Immune System Diseases, STAT3 Transcription Factor, Job Syndrome
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 1 Month to 120 Years
Enrollment: 600 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2000
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Dysfunction; Endocrine, Effects of Chemotherapy, Premature Ovarian Failure
Interventions: Not listed
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2016
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Dementia, Mild Cognitive Impairment, Alzheimer Disease
Interventions: In-Home Technology System and Questionnaires, Waiting Control In-Home Technology System and Questionnaires; Device
Lead sponsor: University of California, Berkeley; Other
Eligibility: 18 Years and older
Enrollment: 216 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Berkeley, California

Conditions: Myocardial Dysfunction, Heart Failure, Inflammation
Interventions: Dapagliflozin, MRI scan, CMR imaging; Drug · Device
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 18 Years to 90 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Alzheimer s Disease, Mild Cognitive Impairment (MCI)
Interventions: Not listed
Lead sponsor: Crownlands; Industry
Eligibility: 55 Years and older
Enrollment: 160 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Germantown, Maryland

Conditions: Mild Cognitive Impairment, Metabolic Syndrome
Interventions: Dietary intervention; Behavioral
Lead sponsor: Bristlecone Health, Inc.; Industry
Eligibility: 35 Years to 80 Years
Enrollment: 98 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Maple Grove, Minnesota

Conditions: Deglutition Disorder, Motor Neuron Disease
Interventions: Not listed
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: Not listed
Enrollment: 750 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1987 – 2005
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Dizziness
Interventions: Centrifugation Distance, Centrifugation Duration, Centrifugation Schedule; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 69 Years
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Mountain Home, Tennessee

Conditions: Complication of Transplanted Liver
Interventions: Not listed
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 207 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Depression, Anxiety
Interventions: Repetitive Transcranial Magnetic Stimulation (rTMS); Device
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years to 60 Years
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Obesity, Endothelial Dysfunction, Decreased Vascular Flow
Interventions: Adenosine, Regadenoson; Drug
Lead sponsor: University of Utah; Other
Eligibility: 18 Years to 88 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Depression
Interventions: riluzole; Drug
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: Not listed
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2003
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Hepatitis B
Interventions: Tenofovir Disoproxil Fumarate, Entecavir; Drug
Lead sponsor: New Discovery LLC; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 2
States / cities: Los Angeles, California • New York, New York

Search by objective public record fields.

Imaging Tau in Alzheimer's Disease and Normal Aging

Georgia Memory Net Anti-Amyloid Monoclonal Antibody Registry

Endothelial Facilitation in Alzheimer's Disease

Trial of Novel Oral Zinc Cysteine Preparation in Alzheimer's Disease

Assessment of Foralumab Safety and Modulation of Microglial Activation in Alzheimer's Disease

Omalizumab to Treat Hyper-IgE (Job's) Syndrome

Reproducibility and Accuracy of a Portable System for Early Detection of Cardiac Dysfunction in Childhood Cancer Survivors

The Effect of an Acute Bout of Exercise on High-sugar Meal Induced Endothelial Dysfunction

Influence of Walnut Intake on Vascular Function and Metabolism

Role of Interferon-gamma 1-b (IFN-γ) on Cells of the Innate Immune System: Functional, Biochemical and Gene Expression Studies in Patients With Chronic Granulomatous Disease

Feasibility and Efficacy of Coronary Sinus Narrowing in Patients With Coronary Microvascular Dysfunction

Natural History, Management, and Genetics of the Hyperimmunoglobulin E Recurrent Infection Syndrome (HIES)

Blood Spot Self-administered Test and Assay

In-Home Technology for Caregivers of People With Dementia and Mild Cognitive Impairment

The Effect of Inflammation in Heart Failure

Crownlands Observing Progression With Neurons Study

Dietary Ketosis: Fatty Acids Activate AMPK Energy Circuits Modulating Global Methylation

Ultrasound and Videofluoroscopy for Diagnosing Swallowing Disorders

Vestibular Rehabilitation and Otolith Dysfunction

Genetic Predisposition-Chronic Nephrotoxicity From CI-Liver Transplant Recipients-Potential Correlation-Urinary Biomarkers

Brief, High-dose rTMS for Depression

Effects of Body Mass Index on the Hyperemic Response to Regadenoson

Riluzole to Treat Major Depression

Tubular Function in Asian-American Patients Receiving TDF or ETV for HBV Treatment